Subsequent caspase-focused analysis highlighted lack of cleaved caspase-3, caspase-7, and caspase-6 in dual CIS/ETP-resistant cell lines following CIS treatment (Fig. 2I). This evidence concerns the gene CASP3 and in situ carcinoma.